OSIS · NASDAQ · Hardware, Equipment & Parts

OSI Systems (OSIS)

Builds security-screening systems, optoelectronic components, and hospital patient-monitoring equipment.

$202.34
vs last close+1.94 (+0.97%)
Loading prices…

OSI Systems, Inc.OSIS
Information Technology

Sells security-screening equipment and turnkey inspection services, optoelectronic components and contract manufacturing, and Spacelabs patient-monitoring and cardiology systems. Security generates most revenue, while vertical integration links component production with finished systems and services.

Designs and manufactures security-inspection systems, optoelectronic components, electronics assemblies, and hospital monitoring products across three divisions. Rapiscan equipment screens baggage, people, cargo, and vehicles, while S2 supplies software and turnkey checkpoint operations.

Produces sensors, laser devices, flex circuits, and other assemblies for internal divisions and OEMs through Optoelectronics and Manufacturing. Spacelabs Healthcare provides bedside and telemetry monitoring, diagnostic cardiology, remote monitoring, and connected-care systems.

Combines in-house component production with final systems, software, maintenance, and staffed screening services for customers across the Americas, Europe, the Middle East, and Asia-Pacific. Security generates most revenue, leaving results tied to government procurement, customer acceptance, export controls, medical-device regulation, and certain single-source components.

Company facts

CEOAjay Mehra
ListedOct 2, 1997
ExchangeNASDAQ
HeadquartersHawthorne, CA
CountryUnited States
Employees7,337
CIK0001039065
ISINUS6710441055

Market cap$3.30B
EPS (ttm)$8.95
P/E (ttm)22.39
ROE17.6%
P/B3.97
P/S1.85
Dividend yieldDiv yield
Beta1.27vs XLK −0.18

Price target$287.00+43.2%Average of 18 analysts
ConsensusBuy16 of 18 analysts
Ratings

Target rangeAs of Sep 21, 2026

Latest analyst notes

DateFirmActionPriorCurrent
Aug 21, 2026Roth CapitalReiterate
Rating: Target: $310
Rating: BuyTarget: $274
Aug 21, 2026OppenheimerReiterate
Rating: Target: $280
Rating: OutperformTarget: $300
May 5, 2026Roth CapitalTarget
Target: $295
Target: $310
Jan 30, 2026Roth CapitalReiterate
Rating: Target: $292
Rating: BuyTarget: $295
Dec 1, 2025UBSTarget
Target:
Target: $292

Next report
Oct 29, 26
in 37 days
EPS estimate
$1.64
Revenue estimate
$397.0M
Fiscal quarter
Q1 FY27

EPSReportedEstimate

Jan '25May '25Aug '25Oct '25Jan '26May '26Aug '26Oct '26
Reported$2.42$2.44$3.24$1.42$2.58$2.60$3.78Pending
Estimate$2.34$2.38$3.19$1.38$2.52$2.53$3.77$1.64
Surprise+3.4%+2.5%+1.6%+2.9%+2.4%+2.8%+0.3%

RevenueReportedEstimate

Jan '25May '25Aug '25Oct '25Jan '26May '26Aug '26Oct '26
Reported$419.8M$444.4M$505.0M$384.6M$464.1M$453.2M$484.1MPending
Estimate$406.6M$436.5M$496.4M$372.0M$449.5M$449.2M$529.7M$397.0M
Surprise+3.2%+1.8%+1.7%+3.4%+3.2%+0.9%−8.6%
Estimate$1.64
ReportedDue Oct 29, 2026
Estimate$397.0M
ReportedDue Oct 29, 2026
View details

Debt to equity120.20%
Current ratio315.30%

ProfitabilityRevenueNet incomeNet margin

Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26
Revenue$344.0M$419.8M$444.4M$505.0M$384.6M$464.1M$453.2M$484.1M
Net income$17.9M$37.8M$41.1M$52.7M$20.6M$38.7M$40.2M$55.2M
Net margin5.2%9.0%9.3%10.4%5.3%8.3%8.9%11.4%

GrowthOperating income

Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26
Operating income$30.3M$58.0M$56.2M$73.0M$33.1M$58.8M$57.4M$69.8M
YoY growth+34.4%−7.7%+85.4%+16.2%+9.1%+1.4%+2.0%−4.5%

Balance sheet, Jun 30, 2026Cash & short-term investments $359.8M · Total debt $1.00B · Total assets $2.50B · Shareholders' equity $833.0M

Revenue
$484.1M
Operating income
$69.8M
Net income
$55.2M
View details

No dividends on record.

Institutions119.97%19.13M shares
375 holders · as of Jun 30, 2026
Insiders6.01%957.4K shares
16 holders · as of Aug 26, 2026
Strategic holders8.10%1.29M shares
2 holders · as of Aug 13, 2026
Adds to134.08%

15.94M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing

These groups come from separate filings that can overlap, so they add to 134.08%; nothing is left for Other.

Top shareholders13F · 13D/G · Form 4

HolderStakeSharesDate
BlackRock, Inc.Institution
16.01%2.55Mas of Jun 30, 2026
FMR LLCInstitution
10.90%1.74Mas of Jun 30, 2026
Vanguard Portfolio Management LLCInstitution
7.98%1.27Mas of Jun 30, 2026
Janus Henderson Group PLCStrategic
5.68%905,925filed Aug 13, 2026
Jupiter Topco LLCInstitution
5.68%905,925as of Jun 30, 2026

Insider tradesForm 4

DateInsiderRoleSharesAvg price
May 4, 2026Deepak Chopradirector−20,000$281.84
Feb 2, 2026Deepak Chopradirector−20,000$250.91
Nov 10, 2025Deepak Chopradirector, officer: EXECUTIVE CHAIRMAN−20,000$285.74
Nov 7, 2025James B. Hawkinsdirector−1,500$283.15
Nov 7, 2025Paul Keith Morbenofficer: PRES., OPTOELECTRONICS DIV−416$279.10
View details

  • iShares MSCI India Small-Cap ETF

    Direct global rival in airport, cargo, and trace detection screening.

  • Leidos

    TSA logistics incumbent and major aviation, ETD, and cargo screening rival.

  • Philips (ADR)

    Scale leader in hospital patient monitoring and connected cardiac care.

  • GE HealthCare

    Global medtech scale leader in patient monitoring, ECG, and anesthesia.

Compare

CompanyPriceChange
OSI Systems$202.34+0.97%$3.30B22.417.81.8−4.1%
iShares MSCI India Small-Cap ETF$70.80−0.37%$696.3M
Leidos$123.93−3.36%$16.13B12.010.30.9+7.2%
Philips (ADR)$24.92+0.06%$24.34B18.712.91.2−2.8%
GE HealthCare$66.27+2.25%$29.27B18.812.71.4+5.8%
Median18.712.71.2+5.8%